文献速递细菌感染、耐药与抗菌药物医院感染防控

BCID2与快速药敏VITEK REVEAL对重症革兰阴性菌血流感染抗生素优化的临床影响:准实验前后对照研究

Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

单中心准实验研究纳入100例ICU首次革兰阴性杆菌血流感染成人患者,比较实施BCID2与VITEK REVEAL快速诊断前后抗生素优化情况。血培养孵育24小时内优化比例无显著差异(28% vs 20%,P=0.3),但阳性血培养24小时内优化比例显著提高(46% vs 26%,P=0.037),优化时间缩短(27h vs 46h,P<0.001)。

要点

  • 快速诊断未提高血培养孵育24h内抗生素优化比例。
  • 阳性血培养24h内优化比例显著提高至46%。
  • 快速诊断组优化时间缩短至27h。

核心结论

  • 真实世界实施BCID2与VITEK REVEAL快速诊断显著缩短结果回报时间,但未改善血培养孵育24小时内抗生素优化。
  • 抗菌药物管理项目可能有助于增强快速诊断工具的临床影响。

研究设计与样本

  • 单中心准实验前后对照研究,比较实施BCID2与VITEK REVEAL前后抗生素优化情况。
  • 纳入ICU首次革兰阴性杆菌血流感染成人患者共100例,前后两个研究期各50例。

主要发现

  • 血培养孵育24小时内优化抗生素治疗比例:干预后28% vs 干预前20%,P=0.3。
  • 阳性血培养24小时内优化抗生素治疗比例:干预后46% vs 干预前26%,P=0.037。
  • 快速诊断组优化时间27h vs 常规组46h,P<0.001。

临床怎么用

  • 快速诊断可缩短重症革兰阴性菌血流感染的结果回报与优化时间。
  • 需结合抗菌药物管理项目以提升快速诊断对临床结局的影响。

局限性

  • 单中心准实验设计,样本量100例,前后各50例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid diagnostic tools (RDT), together with rapid antimicrobial susceptibility testing (rAST), have emerged as means to shorten the time to pathogen identification and AST for bloodstream infections (BSI). Whether these techniques significantly impact antimicrobial therapy in critically ill patients with BSI remains to be determined. METHODS: A single-center quasi-experimental study comparing antibiotic optimisation before and after the implementation of innovative RDT, BIOFIRE® Blood Culture Identification 2 (BCID2) Panel and VITEK® REVEALTM (bioMérieux), was conducted. All adult patients admitted to the intensive care unit (ICU) with a first episode of Gram-Negative Bacilli BSI were included in the study. The primary outcome was the proportion of patients receiving optimized antibiotic therapy within 24 h of blood culture incubation. RESULTS: A total of 100 patients, 50 in each study period, were included. The proportion of patients receiving optimized antibiotic therapy within 24 h of blood culture incubation was not significantly different in the post-interventional (28%) compared with the pre-interventional group (20%) (P = 0.3). When considering antibiotic therapy optimisation within 24 h of positive blood culture, the proportion of patients with optimized antibiotic therapy was significantly higher in the post-intervention group (46% versus 26%, P = 0.037). The time to optimisation in the RDT group was shorter than in the conventional group, 27 h versus 46 h, respectively (P < 0.001). CONCLUSIONS: The real-world implementation of RDT significantly shortened time to results but did not improve antibiotic therapy optimisation within 24 h of blood culture incubation. An antimicrobial stewardship programme could help enhance the clinical impact of RDT.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Oudiane L, Benyahia M, Salipante F, et al. Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study. J Antimicrob Chemother. 2025. PMID: 40754712. doi:10.1093/jac/dkaf271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。